Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 968 across all filing types
Latest filing 2026-04-14 Major Shareholding Noti…
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
ArcticZymes Technologies ASA - flagging
Major Shareholding Notification Classification · 92% confidence The document reports that Belvedere AS has purchased 400,000 shares in ArcticZymes Technologies ASA, resulting in a 5.12% ownership stake – a clear notification of a major shareholding crossing a threshold. This matches the definition of a Major Shareholding Notification (MRQ).
2026-04-14 Norwegian
ArcticZymes Technologies ASA - Capital Markets Day 2026. Scaling a High-Performance Enzyme Platform for Compounding Growth - Attachment: AZT_CMD_2026_Presentation.pdf
Investor Presentation Classification · 100% confidence The document is a presentation titled 'Capital Markets Day 2026' for ArcticZymes Technologies. It contains strategic goals, market analysis, product roadmaps, and financial ambitions presented by the CEO, CFO, and other executives. This is a classic investor presentation used to communicate company strategy and growth prospects to shareholders and analysts, fitting the definition of an Investor Presentation.
2026-03-06 English
ArcticZymes Technologies ASA - Capital Markets Day 2026. Scaling a High-Performance Enzyme Platform for Compounding Growth - Attachment: AZT_CMD_2026_Press_release.pdf
Investor Presentation Classification · 95% confidence The document is a press release announcing and summarizing the content of a 'Capital Markets Day' event. It outlines the company's strategic direction, investment case, and financial ambitions presented during the event. According to the provided definitions, documents detailing presentations and materials shared during investor-focused events (like a Capital Markets Day) are classified as Investor Presentations (IP).
2026-03-06 English
ArcticZymes Technologies ASA - Capital Markets Day 2026. Scaling a High-Performance Enzyme Platform for Compounding Growth
Report Publication Announcement Classification · 95% confidence The document is an announcement regarding a 'Capital Markets Day' event. It outlines the company's strategic direction, financial ambitions, and investment case, which are typical contents of an investor presentation. However, the document itself serves as a press release/announcement summarizing the event and providing links to the actual presentation materials (webcast and replay). According to the 'Menu vs Meal' rule, since this is an announcement of an event/presentation rather than the presentation deck itself, it is classified as a Report Publication Announcement (RPA).
2026-03-06 English
ArcticZymes Technologies ASA: Reminder - Capital Markets Day, 6 March 2026
Regulatory Filings Classification · 95% confidence The document is an announcement regarding an upcoming 'Capital Markets Day' event. It provides details on the date, venue, agenda, and speakers, and invites stakeholders to attend. It does not contain the actual presentation materials themselves, but rather serves as a notification/invitation for the event. Since it is an announcement of an upcoming investor-focused event, it falls under the category of Regulatory Filings (RNS) as it does not fit the specific criteria for an Investor Presentation (which would be the slides themselves) or other specific categories.
2026-03-03 English
ArcticZymes Releases New White Paper Quantifying the Impact of Optimized Nuclease Strategy on Viral Vector Manufacturing Economics - Attachment: Economics_of_SAN_26022026.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of a white paper by ArcticZymes Technologies. It describes the content of the white paper, provides key findings, and includes a link for readers to download the document. Since it is an announcement regarding the release of a document rather than a formal financial report, regulatory filing, or mandatory disclosure, it falls under the category of a general regulatory announcement or corporate news update. Given the provided categories, 'RNS' (Regulatory Filings) serves as the appropriate fallback for this type of corporate communication.
2026-02-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.